Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Archives of Clinical Psychiatry |
Texto Completo: | https://www.revistas.usp.br/acp/article/view/144883 |
Resumo: | Background Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for 2-3 weeks after the experimental session in 17 patients with treatment-resistant major depressive disorder. Objectives To investigate if the experiment had any long-lasting effects on patients Methods Eight patients were interviewed 4 to 7 years after ayahuasca intake. Results Our results suggest that ayahuasca was well tolerated and that symptom reductions were limited to a few weeks. Importantly, most patients believed that the experience was among the most important of their lives, even 4-7 years later. Discussion To the best of our knowledge, this is the first long-term follow-up of a clinical sample that participated in an ayahuasca trial. Further studies with different and repeated dosing should be designed to further explore the antidepressive and anxiolytic effects of ayahuasca. |
id |
USP-5_f36b9397668cdc3d3e9e7431b9babca0 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/144883 |
network_acronym_str |
USP-5 |
network_name_str |
Archives of Clinical Psychiatry |
repository_id_str |
|
spelling |
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-upHallucinogenspsychedelicsayahuascadepressionsafety Background Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for 2-3 weeks after the experimental session in 17 patients with treatment-resistant major depressive disorder. Objectives To investigate if the experiment had any long-lasting effects on patients Methods Eight patients were interviewed 4 to 7 years after ayahuasca intake. Results Our results suggest that ayahuasca was well tolerated and that symptom reductions were limited to a few weeks. Importantly, most patients believed that the experience was among the most important of their lives, even 4-7 years later. Discussion To the best of our knowledge, this is the first long-term follow-up of a clinical sample that participated in an ayahuasca trial. Further studies with different and repeated dosing should be designed to further explore the antidepressive and anxiolytic effects of ayahuasca.Universidade de São Paulo. Faculdade de Medicina. Instituto de Psiquiatria2018-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/acp/article/view/14488310.1590/0101-60830000000149Archives of Clinical Psychiatry; v. 45 n. 1 (2018); 22-24Archives of Clinical Psychiatry; Vol. 45 No. 1 (2018); 22-24Revista de Psiquiatria Clínica; Vol. 45 Núm. 1 (2018); 22-241806-938X0101-6083reponame:Archives of Clinical Psychiatryinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/acp/article/view/144883/139110Copyright (c) 2018 Archives of Clinical Psychiatryinfo:eu-repo/semantics/openAccessSantos, Rafael G. DosSanches, Rafael FariaOsório, Flávia de LimaHallak, Jaime E. C.2018-03-29T16:34:04Zoai:revistas.usp.br:article/144883Revistahttp://www.hcnet.usp.br/ipq/revista/index.htmlPUBhttps://old.scielo.br/oai/scielo-oai.php||archives@usp.br1806-938X0101-6083opendoar:2018-03-29T16:34:04Archives of Clinical Psychiatry - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up |
title |
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up |
spellingShingle |
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up Santos, Rafael G. Dos Hallucinogens psychedelics ayahuasca depression safety |
title_short |
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up |
title_full |
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up |
title_fullStr |
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up |
title_full_unstemmed |
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up |
title_sort |
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up |
author |
Santos, Rafael G. Dos |
author_facet |
Santos, Rafael G. Dos Sanches, Rafael Faria Osório, Flávia de Lima Hallak, Jaime E. C. |
author_role |
author |
author2 |
Sanches, Rafael Faria Osório, Flávia de Lima Hallak, Jaime E. C. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Santos, Rafael G. Dos Sanches, Rafael Faria Osório, Flávia de Lima Hallak, Jaime E. C. |
dc.subject.por.fl_str_mv |
Hallucinogens psychedelics ayahuasca depression safety |
topic |
Hallucinogens psychedelics ayahuasca depression safety |
description |
Background Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for 2-3 weeks after the experimental session in 17 patients with treatment-resistant major depressive disorder. Objectives To investigate if the experiment had any long-lasting effects on patients Methods Eight patients were interviewed 4 to 7 years after ayahuasca intake. Results Our results suggest that ayahuasca was well tolerated and that symptom reductions were limited to a few weeks. Importantly, most patients believed that the experience was among the most important of their lives, even 4-7 years later. Discussion To the best of our knowledge, this is the first long-term follow-up of a clinical sample that participated in an ayahuasca trial. Further studies with different and repeated dosing should be designed to further explore the antidepressive and anxiolytic effects of ayahuasca. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-02-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/acp/article/view/144883 10.1590/0101-60830000000149 |
url |
https://www.revistas.usp.br/acp/article/view/144883 |
identifier_str_mv |
10.1590/0101-60830000000149 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/acp/article/view/144883/139110 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Archives of Clinical Psychiatry info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Archives of Clinical Psychiatry |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Medicina. Instituto de Psiquiatria |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Medicina. Instituto de Psiquiatria |
dc.source.none.fl_str_mv |
Archives of Clinical Psychiatry; v. 45 n. 1 (2018); 22-24 Archives of Clinical Psychiatry; Vol. 45 No. 1 (2018); 22-24 Revista de Psiquiatria Clínica; Vol. 45 Núm. 1 (2018); 22-24 1806-938X 0101-6083 reponame:Archives of Clinical Psychiatry instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Archives of Clinical Psychiatry |
collection |
Archives of Clinical Psychiatry |
repository.name.fl_str_mv |
Archives of Clinical Psychiatry - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||archives@usp.br |
_version_ |
1800237624175099904 |